1001756-21-3

Basic information

• Product Name: 4-amino-6-chloronicotinaldehyde
• Synonyms: 4-amino-6-chloronicotinaldehyde
• CAS NO: 1001756-21-3
• Molecular Formula: C₆H₅ClN₂O
• Molecular Weight: 156.5697
• Mol File: 1001756-21-3.mol

Chemical Properties

• Boiling Point: 379.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.442±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.58±0.42(Predicted)
• CAS DataBase Reference: 4-amino-6-chloronicotinaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-6-chloronicotinaldehyde(1001756-21-3)
• EPA Substance Registry System: 4-amino-6-chloronicotinaldehyde(1001756-21-3)

Safety Data

• Hazardous Substances Data: 1001756-21-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
4-amino-6-chloronicotinaldehyde is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic benefits.
Used as an Anti-tuberculosis Agent:
In the field of medicinal chemistry, 4-amino-6-chloronicotinaldehyde is studied for its potential as an anti-tuberculosis agent. Its ability to target and inhibit the growth of Mycobacterium tuberculosis, the causative agent of tuberculosis, makes it a promising candidate for the development of new anti-tuberculosis drugs.
Used in the Development of Fluorescent Probes for Biological Imaging:
4-amino-6-chloronicotinaldehyde has been investigated for its potential use in the development of fluorescent probes for biological imaging. Its fluorescent properties allow for the visualization and tracking of cellular processes, making it a valuable tool in the field of biochemistry and molecular biology.
Used in Antibacterial and Antifungal Applications:
Due to its inherent antibacterial and antifungal properties, 4-amino-6-chloronicotinaldehyde is used in various applications to combat microbial infections. It can be incorporated into pharmaceutical formulations, disinfectants, and other products to enhance their antimicrobial efficacy.
Used in Organic Synthesis:
In the field of organic synthesis, 4-amino-6-chloronicotinaldehyde serves as a versatile building block for the synthesis of a wide range of organic compounds. Its reactive functional groups enable various chemical transformations, making it a valuable component in the synthesis of complex organic molecules.

InChI:InChI=1S/C6H5ClN2O/c7-6-1-5(8)4(3-10)2-9-6/h1-3H,(H2,8,9)

Upstream product

• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 1588423-42-0 ethyl 6-chloro-4-((2,4-dimethoxybenzyl)amino)nicotinate 
• 380626-81-3 ethyl 4-amino-6-chloropyridine-3-carboxylate 
• 1391740-89-8 ethyl 6-chloro-4-[(4-methoxyphenyl)methylamino]pyridine-3-carboxylate 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 1256785-40-6 methyl 4-amino-6-chloro-pyridine-3-carboxylate 
• 1374215-05-0 methyl 4-(benzylamino)-6-chloronicotinate 
• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 846036-96-2 (4-amino-6-chloropyridin-3-yl)methanol 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 

Downstream Products

• 1386447-86-4 3-({7-[(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-amino]-2-oxo-1,2-dihydro-[1,6]naphthyridine-3-carbonyl}-amino)-benzoic acid methyl ester 
• 1455035-79-6 5-(7-chloro-2-methyl-1,6-naphthyridin-3-yl)-2-fluoroaniline 
• 1588422-41-6 C₃₁H₃₁N₅O₂ 
• 1588422-66-5 3-(2,6-difluorophenyl)-7-((5-fluoropyridin-2-yl)amino)-1-phenyl-1,6-naphthyridin-2(1H)-one 
• 1588423-44-2 7-chloro-1-methyl-3-phenyl-1,6-naphthyridin-2-(1H)-one 
• 1588423-58-8 C₂₀H₁₁ClF₂N₂O 
• 1588423-92-0 C₂₀H₁₃ClN₂O 
• 1588423-93-1 C₁₇H₁₅ClN₂O 
• 1588421-99-1 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-3-phenyl-1H-[1,6]naphthyridin-2-one 
• 1588422-00-7 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-1-methyl-3-phenyl-1H-[1,6]naphthyridin-2-one 
• 1588422-03-0 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-3-isopropyl-1-phenyl-1H-[1,6]naphthyridin-2-one 
• 1588423-43-1 C₁₄H₉ClN₂O 
• 1588423-57-7 C₁₄H₇ClF₂N₂O 

Relevant articles and documents

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3- d ]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells

The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficac

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for

MULTIPLE KINASE PATHWAY INHIBITORS

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

RAF INHIBITOR COMPOUNDS

This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.

1,6- AND 1,8-NAPHTHYRIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.